Kura Oncology’s Strategic Advancements and Promising Pipeline Drive Buy Rating

Jonathan Chang, an analyst from Leerink Partners, reiterated the Buy rating on Kura Oncology (KURA – Research Report). The associated price target remains the same with $23.00.

Jonathan Chang has given his Buy rating due to a combination of factors, primarily centered around Kura Oncology’s promising pipeline developments and strategic progress. The company reported financial results for the first quarter of 2025 that aligned with expectations, highlighting significant advancements in their clinical trials.
The successful achievement of the primary endpoint in the KOMET-001 trial for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia and the subsequent NDA submission with a priority review request are pivotal milestones. Additionally, the acceptance of ziftomenib data for presentations at major conferences like ASCO and EHA further underscores the potential of their menin inhibitors. The continued expansion into other therapeutic areas and the progress in their farnesyl transferase inhibitor franchise, including the anticipated clinical data for KO-2806, reinforce the long-term growth prospects for Kura Oncology.

In another report released on May 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.